A Phase I, open-label study in healthy adults comparing the availability in the body of the active substance lidocaine following administration of 2% and 4% lidocaine gel into the urethra

2026-525752-29-00 Protocol LIDEXU Human pharmacology (Phase I) - Bioequivalence study Ongoing, recruiting

Start 1 Jun 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol LIDEXU

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ongoing, recruiting
Participants planned 28
Countries 1
Sites 1

bioavailability trial with healthy participants, therapeutic indication not studied

Key facts

Sponsor
Farco-Pharma GmbH
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03], Diseases [C] - Male Urogenital Diseases [C12], Diseases [C] - Female Urogenital Diseases and Pregnancy Complications [C13]
Trial duration
1 Jun 2026 → ongoing
Decision date (initial)
2026-05-05
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

bioavailability trial with healthy participants, therapeutic indication not studied

VersionLevelCodeTermSystem organ class
20.0 PT 10024758 Local anaesthesia 100000004865
21.1 PT 10062224 Urethral operation 100000004865
21.1 PT 10005028 Bladder catheterisation 100000004865
21.0 PT 10011814 Cystoscopy 100000004848
28.0 PT 10036786 Proctoscopy 100000004848
20.0 PT 10011781 Cystitis 100000004862
20.1 PT 10045434 Ultrasound scan 100000004848

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Farco-Pharma GmbH

Sponsor organisation
Farco-Pharma GmbH
Address
Gereonsmuehlengasse 1-11, Altstadt-Nord Altstadt-Nord
City
Cologne
Postcode
50670
Country
Germany

Scientific contact point

Organisation
Farco-Pharma GmbH
Contact name
Dr. Jennifer Vollmer

Public contact point

Organisation
Farco-Pharma GmbH
Contact name
Dr. Jennifer Vollmer

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruiting 28 1
Rest of world 0

Investigational sites

Germany

1 site · Ongoing, recruiting
SocraTec R&D Concepts in Drug Research and Development GmbH
CPU, Mainzerhofplatz 14, Erfurt-Altstadt, Erfurt

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2026-06-01 2026-06-01

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-03-27 Germany Acceptable
2026-05-04
2026-05-05